olivLaw · US equity research
Sanofi SNY
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Sanofi is an R&D driven, AI-powered biopharma company active in immunology, rare diseases, neurology, oncology and vaccines. Net sales for 2025 reached €43,626 million, with growth of 9.9% at constant exchange rates driven mainly by Dupixent, which makes the company relevant amid pricing pressure and generic erosion of revenues.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Sanofi (SNY) stock was 47.47 USD (+4.72% on the day), with beta 0.30, 52-week range 39.12–52.34 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 77.3
- overbought (≥ 70)
- Bollinger (20, 2)
- 37.43 – 46.27
- above the upper band · %B 1.14 · band width 21.1%
- SMA 50 / 200
- 42.22 / 44.32
- mixed trend
- MACD (12, 26, 9)
- 1.11 / 0.38
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +20.1% | −1.1% | +21.2 pp | — |
| 3 months | +11.0% | −0.5% | +11.4 pp | — |
| 6 months | +8.5% | +4.4% | +4.1 pp | — |
| Year to date | −2.0% | +12.3% | −14.4 pp | — |
| 1 year | −3.3% | +13.5% | −16.9 pp | −9.2% |
| 3 years | +3.6% | +76.4% | −72.8 pp | +50.7% |
| 5 years | −7.4% | +63.7% | −71.1 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | 4.3 bn | 2.8 bn | 12.3 bn | 6.2 bn | 8.4 bn | 5.4 bn | 5.6 bn | 7.8 bn |
| Net income YoY | −48.8% | −36.0% | +346.4% | −49.4% | +34.5% | −35.5% | +3.0% | +40.5% |
| Diluted EPS | 3.43 | 2.23 | 9.77 | unavailable | 6.66 | 4.30 | 4.43 | 6.37 |
| Diluted EPS YoY | −48.3% | −35.0% | +338.1% | unavailable | unavailable | −35.4% | +3.0% | +43.8% |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.7 bn EUR
- Financial debt
- 14.2 bn EUR
- Net debt
- 6.6 bn EUR
- Equity
- 71.7 bn EUR
- Total assets
- 126.8 bn EUR
- Debt / equity
- 0.20x
- Current ratio
- 1.09x
- ROE
- 10.4%
- ROA
- 6.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Income statement · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cost of revenue | 12.2 bn | 12.3 bn | 11.9 bn | 12.6 bn | 13.2 bn | 13.0 bn | SEC (XBRL)· 17 Feb 2026verified |
| Gross profit | 25.2 bn | 26.9 bn | 28.7 bn | 29.0 bn | 31.1 bn | 33.7 bn | SEC (XBRL)· 17 Feb 2026verified |
| Research & development | 5.5 bn | 5.7 bn | 6.5 bn | 6.5 bn | 7.4 bn | 7.8 bn | SEC (XBRL)· 17 Feb 2026verified |
| Operating income | 14.1 bn | 8.1 bn | 10.2 bn | 7.0 bn | 7.3 bn | 6.3 bn | SEC (XBRL)· 17 Feb 2026verified |
| Interest expense | 388.0 m | 368.0 m | 430.0 m | 1.3 bn | 1.1 bn | 563.0 m | SEC (XBRL)· 17 Feb 2026verified |
| Income tax | 1.8 bn | 1.6 bn | 1.9 bn | 1.0 bn | 1.2 bn | 1.0 bn | SEC (XBRL)· 17 Feb 2026verified |
| Net income | 12.3 bn | 6.2 bn | 8.4 bn | 5.4 bn | 5.6 bn | 7.8 bn | SEC (XBRL)· 17 Feb 2026verified |
| Diluted EPS | 9.77 | — | 6.66 | 4.30 | 4.43 | 6.37 | SEC (XBRL)· 17 Feb 2026verified |
| Weighted average diluted shares | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.2 bn | SEC (XBRL)· 17 Feb 2026verified |
Balance sheet · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 13.9 bn | 10.1 bn | 12.7 bn | 8.7 bn | 7.4 bn | 7.7 bn | SEC (XBRL)· 17 Feb 2026verified |
| Inventories | 8.4 bn | 8.7 bn | 9.0 bn | 9.7 bn | 9.4 bn | 10.2 bn | SEC (XBRL)· 17 Feb 2026verified |
| Current assets | — | — | 34.1 bn | 30.7 bn | 42.6 bn | 31.0 bn | SEC (XBRL)· 17 Feb 2026verified |
| Property, plant & equipment, net | 9.4 bn | 10.0 bn | 9.9 bn | 10.2 bn | 10.1 bn | 10.1 bn | SEC (XBRL)· 17 Feb 2026verified |
| Goodwill | 44.4 bn | 48.1 bn | 49.9 bn | 49.4 bn | 43.4 bn | 41.3 bn | SEC (XBRL)· 17 Feb 2026verified |
| Intangibles (excl. goodwill) | 18.3 bn | 21.4 bn | 21.6 bn | 24.3 bn | 22.6 bn | 26.3 bn | SEC (XBRL)· 17 Feb 2026verified |
| Total assets | 114.4 bn | 120.2 bn | 126.7 bn | 126.5 bn | 132.8 bn | 126.8 bn | SEC (XBRL)· 17 Feb 2026verified |
| Long-term debt | 19.7 bn | 17.1 bn | 14.9 bn | 14.3 bn | 11.8 bn | 14.2 bn | SEC (XBRL)· 17 Feb 2026verified |
| Current liabilities | — | — | 24.0 bn | 24.2 bn | 29.2 bn | 28.3 bn | SEC (XBRL)· 17 Feb 2026verified |
| Equity | 63.3 bn | 69.0 bn | 75.2 bn | 74.4 bn | 77.9 bn | 71.7 bn | SEC (XBRL)· 17 Feb 2026verified |
| Shares outstanding at year end | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.2 bn | SEC (XBRL)· 17 Feb 2026verified |
Cash flow · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.4 bn | 10.5 bn | 10.5 bn | 10.3 bn | 9.1 bn | 10.8 bn | SEC (XBRL)· 17 Feb 2026verified |
| Investing cash flow | 3.6 bn | -7.3 bn | -2.1 bn | -6.2 bn | -4.4 bn | -2.4 bn | SEC (XBRL)· 17 Feb 2026verified |
| Financing cash flow | -6.5 bn | -7.1 bn | -5.8 bn | -8.1 bn | -5.8 bn | -8.2 bn | SEC (XBRL)· 17 Feb 2026verified |
| Share repurchases | 822.0 m | 382.0 m | 497.0 m | 593.0 m | 302.0 m | 5.0 bn | SEC (XBRL)· 17 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 29.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
29% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 95.21 – 277.98 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E95.21 – 277.98 (Mid 185.67)14 companies used · median multiple 29.1x · quartiles 14.9x – 43.6xABBV, ABT, ALNY, AUPH, BMY, JNJ, LLY, NATR, PFE, REGN, RPRX, UTHR, VRTX, ZTS
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 6.6% | 33 (vs peers) | 36% |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | -1.5% | 0 (on a fixed band) | 29% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 11.3x | 100 (on a fixed band) | 21% |
| Current ratio · Balance sheet | 1.1x | 24 (on a fixed band) | 14% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet70/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial33/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Sanofi (SNY). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: ROE 10.5%.
The estimated value range is 95.21–277.98 EUR per share (median of 1 methods, agreement: single method); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Interest coverage: 11.3x
What contradicts it
- EPS CAGR 3Y: -1.5%
- Current ratio: 1.1x
Not assessed (insufficient data or a ratio without meaning): Net margin, FCF conversion, Revenue CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| IONSIonis Pharmaceuticals, Inc. | 6.7 bn | — | -105.5% | -64.7% | +33.8% | −51% / −19% |
| IDYAIDEAYA Biosciences, Inc. | 3.1 bn | — | -38.5% | -1,149.6% | +3,024.4% | −9% / +3% |
| RADXRadiopharm Theranostics Limited | 3.1 bn | — | -109.2% | -1,055.3% | +1,114.3% | −81% / unavailable |
| AUPHAurinia Pharmaceuticals Inc. | 2.3 bn | 7.5 | 61.4% | 97.7% | +20.4% | +6% / +98% |
| QUREuniQure N.V. | 1.6 bn | — | -89.0% | -1,154.8% | −40.6% | −16% / +240% |
| URGNUroGen Pharma Ltd. | 1.4 bn | — | — | -26.3% | +21.4% | −0% / +118% |
| ASMBAssembly Biosciences, Inc. | 404.6 m | — | -0.0% | -0.1% | +153.5% | −47% / +137% |
1- and 3-year price returns: for SNY from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 17 Feb 2026; since then the company filed 6-K (30 Oct 2026), 6-K (26 Oct 2026), 6-K (01 Oct 2026), 6-K (17 Sept 2026), 6-K (06 Aug 2026), 6-K (30 Jul 2026).
In brief
Sanofi is an R&D driven, AI-powered biopharma company active in immunology, rare diseases, neurology, oncology and vaccines. Net sales for 2025 reached €43,626 million, with growth of 9.9% at constant exchange rates driven mainly by Dupixent, which makes the company relevant amid pricing pressure and generic erosion of revenues 1.
SWOT
Strengths
- A portfolio of fast-growing medicines, particularly Dupixent, supports revenue and provides a solid base for research investment 1.
- The company's financial position has allowed significant acquisitions and a share buyback programme 1.
- Technology and manufacturing platforms, including mRNA, give the company differentiated capabilities 1.
Weaknesses
- Several important products face erosion from generic and biosimilar competition, reducing revenue from mature products 1.
- The portfolio relies on a few key products, and losing their exclusivity could affect results 1.
- The company carries high compliance costs and exposure to litigation over pricing and commercial practices 1.
Opportunities
- If recent acquisitions and pipeline candidates reach approval, they could open new markets in immunology, neurology and vaccines 1.
- Use of artificial intelligence in research and manufacturing could shorten development times and reduce production costs 1.
- Expanding US manufacturing capacity could strengthen the company's position in the largest pharmaceutical market 1.
Threats
Risks
- Pricing and commercial practice litigationhigh
Sanofi is the target of several lawsuits on pricing and marketing practices, including 340B drug pricing litigation in the United States, which could lead to fines or restrictions 1.
- Generic competition erosionmedium
Continued erosion of mature products could reduce revenue and profit in coming years, particularly for Aubagio, Lovenox and Lantus 1.
- Regulatory and compliance riskmedium
Authority inspections and warning letters on manufacturing practices could delay launches or approvals, and US policy changes add uncertainty 1.
- Integration and research riskmedium
Recent acquisitions involve payments contingent on development milestones, and failure of clinical studies could reduce their value 1.
Investment thesis
What would need to be true (bull case)
- If Dupixent and new medicines keep growing, the company could offset losses from generics with a more diversified portfolio 1.
- The 2025 acquisitions in immunology and neurology could add long-term value if development milestones are achieved 1.
- The efficiency programme and use of artificial intelligence could improve operating margins in coming years 1.
What would break the thesis
- Continued erosion of mature products could reduce revenue faster than expected if new launches do not compensate 1.
- Litigation over product liability and pricing practices could generate unforeseen costs or commercial restrictions 1.
- Government pressure on prices could limit margin growth, especially if US agreements extend to other countries 1.
What to watch
- Quarterly results and Dupixent sales trajectoryQ1 2027
- Completion of the Dynavax acquisition and its integration2026
- Evolution of erosion for Aubagio, Lovenox and Lantus2027
- Status of product liability and US pricing proceedingsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 17 Feb 2026; since then the company filed 6-K (30 Oct 2026), 6-K (26 Oct 2026), 6-K (01 Oct 2026), 6-K (17 Sept 2026), 6-K (06 Aug 2026), 6-K (30 Jul 2026).
The business
Sanofi's activity is organized as a single operating segment, Biopharma, comprising commercial operations and research, development and production for the Specialty Care, General Medicines and Vaccines franchises, across all geographies 1. Activities are grouped into Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines 1. The company's 'Take the Lead' strategy focuses on growth, innovation, efficiency and reinventing how it works, with AI integrated into research and manufacturing 1.
In 2025 Sanofi completed several acquisitions to build its pipeline, including Blueprint Medicines, which added Ayvakit/Ayvakyt, Vigil Neuroscience, DR-0201 from Dren Bio, and Vicebio, an early-stage combination vaccine candidate against RSV and hMPV 1. It also announced an agreement to acquire Dynavax Technologies, expected to close in the first quarter of 2026 1. In April 2025 it closed the transaction transferring a controlling stake in Opella to CD&R, which produced a net gain of €2.6 billion 1.
On capital allocation, the Board authorized a share buyback of up to €5 billion, and the proposed dividend for 2025 is €4.12 per share, a payout of 52.6% of business net income per share 1. The company issued bonds in European and US markets for general corporate purposes 1.
Segments
Market context
Sanofi notes that demographic trends and high unmet medical needs support long-term demand for medicines and vaccines, while pressure on healthcare costs and price scrutiny by payers are rising 1. Generic and biosimilar competition already affects some flagship products, and the company expects erosion to continue in 2026, with a negative impact on net income 1. Policy changes in the US could make pricing and reimbursement conditions in that market evolve in hard-to-anticipate ways 1.
The vaccines and immunology markets remain competitive, with innovation, real-life outcome evidence and price transparency becoming decisive criteria 1. The company considers pharmaceuticals and vaccines to remain an attractive part of the value chain, although the bar for innovation could keep rising 1.
Trends
- Pricing pressure and the US government agreementmixed
Sanofi entered a voluntary agreement with the US government to align Medicaid prices of certain medicines with those in other high-income countries, with an average reduction announced for certain treatments, in exchange for a three-year period free from Section 232 tariffs 1. The company stated the agreement is not expected to have a material impact on its growth strategy over the period covered 1.
- Generic and biosimilar competitionheadwind
Products such as Aubagio, Lovenox and Lantus already show sales erosion, and the company expects this trend to continue in 2026 1. If the pace of erosion accelerates, pressure on profit could increase 1.
- Artificial intelligence in research and manufacturingtailwind
Sanofi invests in AI tools for drug discovery, clinical trial design and manufacturing optimization, and reports efficiency gains in its production processes 1. Initial results are accompanied by caveats that they remain subject to ongoing validation 1.
- Consolidation through biotech acquisitionsmixed
The 2025 acquisition series extends the pipeline in immunology, neurology and vaccines, but also brings integration risks and payments contingent on development milestones 1. Their impact on results depends on those milestones being met 1.
Competitive position
Sanofi competes in pharmaceutical markets with companies developing immunology therapies, vaccines and rare disease medicines, mainly through innovation and patient access 1. Pressure from generic and biosimilar competition on mature products is a permanent part of the competitive environment 1.
In vaccines, the company faces players developing next-generation RSV and influenza vaccines, and its recent acquisitions aim to strengthen its position 1. Technological differentiation, such as the molecular clamp technology for fully liquid combination vaccines, is an important factor 1.
- Biotech companies with immunology therapies and vaccines
The source refers to competition from new developers of vaccines and immunology therapies without naming specific competitors in the filing text 1.
- Biosimilar and generic manufacturers
On mature products, competition comes from biosimilars and generics, which have reduced sales of some of the company's medicines in Europe, the US and Japan 1.
- Developers of respiratory vaccines
Sanofi acquired a company with an RSV and hMPV combination vaccine candidate, an area where several developers operate, not named in the source 1.
- Companies with therapies for mastocytosis and rare immune diseases
The Blueprint acquisition placed Sanofi in a segment with specialized competitors in rare immune system disorders, not detailed in the source 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Buğra Kulak, Sanofi România: Costul unui tratament nu spune întreaga poveste despre valoarea sa pentru sistemul de sănătateProfit.ro · 02 Nov 2026 · RO
- STAT+: Pharmalittle: We’re reading about Sanofi settling an EU antitrust probe, ‘pharma bro’ Shkreli, and moreSTAT News · 14 Oct 2026 · EN
- STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccineSTAT News · 14 Oct 2026 · EN
- STAT+: Sanofi, Regeneron expand partnership after Dupixent successSTAT News · 01 Oct 2026 · EN
- Cheplapharm to take over 20 medicines and three sites from SanofiYahoo Finance — News · 15 Sept 2026 · EN
- Compania farmaceutică Sanofi, vizată de o anchetă a UE în urma unor suspiciuni de concurenţă neloialăMoney.ro · 26 Jun 2026 · RO
- Investigație privind promovarea de către Sanofi a unui vaccin antigripalJuridice.ro · 26 Jun 2026 · RO
- Sanofi, investigată de CEJuridice.ro · 26 Jun 2026 · RO
- Buğra Kulak, Country Lead şi Head of Pharma, Sanofi România: AI poate accelera descoperirea, dar fără registre de pacienţi şi date din lumea reală, sistemele de sănătate nu pot livra inovaţie la scară largăZiarul Financiar · 11 May 2026 · RO
SEC filings
- Current report (foreign issuer)30 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)01 Oct 2026
- Current report (foreign issuer)17 Sept 2026
- Current report (foreign issuer)06 Aug 2026
- Current report (foreign issuer)30 Jul 2026
- Current report (foreign issuer)30 Jul 2026
- Current report (foreign issuer)27 Jul 2026
- Current report (foreign issuer)17 Jul 2026
- Current report (foreign issuer)07 Jul 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Sanofi · 17 Feb 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.